Evidence map›Paper›PMID 33221285›Full record

Trial reportAmerican journal of ophthalmology2021

Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Avni P Finn, Maxwell Pistilli, Vincent Tai, Ebenezer Daniel, Gui-Shuang Ying, Maureen G Maguire, Juan E Grunwald, Daniel F Martin, Glenn J Jaffe, Cynthia A Toth and 1 more

Open access · greenAbstract readClinical TrialComparative StudyMulticenter Study
In one paragraph

Trial report in American journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Imaging biomarkers and artificial intelligence for diagnosis, prediction, and therapy of macular fibrosis in age-related macular degeneration: Narrative review and future directions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Avni P FinnNorthern California Retina Vitreous Associates, Mountain View, California, USA.
Maxwell PistilliDepartment of Ophthalmology, University of Pennsylvania, Pennsylvania, Philadelphia, USA.
Vincent TaiDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA.
Ebenezer DanielDepartment of Ophthalmology, University of Pennsylvania, Pennsylvania, Philadelphia, USA.
Gui-Shuang YingDepartment of Ophthalmology, University of Pennsylvania, Pennsylvania, Philadelphia, USA.
Maureen G MaguireDepartment of Ophthalmology, University of Pennsylvania, Pennsylvania, Philadelphia, USA.
Juan E GrunwaldDepartment of Ophthalmology, University of Pennsylvania, Pennsylvania, Philadelphia, USA.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA.
Cynthia A TothDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA; Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA. Electronic address: cynthia.toth@duke.edu.
Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group
University of Pennsylvania · USDuke University · USCleveland Clinic · USRetina Vitreous Associates of Florida · US

Funding

Coordinating Center for the Comparison of AMD Treatments TrialsU10EY017823 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2006 to 2012
$19.2M
Follow-up Study: Comparison of AMD Treatments Trial (CATT)U10EY023530 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2013 to 2016
$3.5M
Photograph Reading Center for the Comparison of AMD Treatment TrialsU10EY017826 · NEI · UNIVERSITY OF PENNSYLVANIA · PI GRUNWALD, JUAN E · 2006 to 2013
$2.8M
Comparison of AMD Treatment Trials-OCT Reading CenterU10EY017825 · NEI · DUKE UNIVERSITY · PI JAFFE, GLENN · 2006 to 2013
$2.3M
Chair Grant for the Comparison of AMD Treatment TrialsU10EY017828 · NEI · EMORY UNIVERSITY · PI MARTIN, DANIEL F · 2006 to 2012
$1.9M
NEI NIH HHS U10 EY017823NEI NIH HHS U10 EY017825NEI NIH HHS U10 EY017826NEI NIH HHS U10 EY017828NEI NIH HHS U10 EY023530
6 · The paper itself

Abstract

purposeTo identify precursors of macular atrophy (MA) and of fibrotic scar (FS) in eyes treated with anti-vascular endothelial growth factor through pixel-mapping analysis of baseline optical coherence tomography (OCT).

methodsDesign: Cross-sectional analysis.

settingMulticenter clinical trial. PATIENT POPULATION: 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials.

interventionTreatment with anti-vascular endothelial growth factor agents.

main outcome measureThe percentage of MA or FS pixels with each OCT feature at baseline, and the odds ratio for baseline pixels with an OCT feature to develop MA or FS.

resultsRetinal pigment epithelium atrophy and photoreceptor loss on OCT were highly predictive of MA at that location at years 2 and 5 (P < .0001), but accounted for only 22.5% of the ensuing atrophy at year 2 and less at year 5. Among pixels of MA at year 2, 78% were preceded by thick drusen, 54% by subretinal macular neovascularization (MNV), and 22.5% by no detectable OCT features. MNV, subretinal hyperreflective material, pigment epithelial detachment, intraretinal fluid, and sub-retinal pigment epithelium fluid were predictive of FS at that location (P values <.05). More than 75% of the pixels of FS at years 2 and 5 were preceded by pixels of baseline MNV.

conclusionsMost pixels of FS were preceded by components of neovascularization. Although one-quarter of MA was accounted for by pre-existing evidence of atrophy on OCT alone, the development of MA in areas of thick drusen, areas with and without subretinal MNV lesion, and areas without detectable OCT precursors argues that the development of MA is multifactorial and may follow, in part, a non-neovascular pathway.

Indexed as

Visual AcuityAgedAged, 80 and overAngiogenesis InhibitorsCicatrixCross-Sectional StudiesFemaleFluorescein AngiographyFundus OculiHumansIntravitreal InjectionsMacular DegenerationMaleMiddle AgedTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID33221285
PMCPMC7979472
OpenAlexW3103964456

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.